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measurers was 0.816 (p  0.0001). Cost/QALY exceeded cost/life-year in 61% of cases 
whereas cost/life-year exceeded cost/QALY in 39% of cases. In 124 (84%) of com-
parisons, both cost/QALY and cost/life-year ratios were below a pre-speciﬁed thresh-
old (e.g., $50,000 per QALY or life-year). In 14 (10%) of cases, adjusting for quality 
of life resulted in a ratio that crossed the $50,000 value, whereas in 4(3%) the cost/
QALY ratio crossed the $100,000 threshold. CONCLUSIONS: Adjusting life years 
for HRQL does not substantively affect cost per life year ratios for the vast majority 
of published cancer interventions in our sample. The results suggest that the method 
used for quality adjusting or even quality adjusting at all may not matter for cost-
effectiveness analyses of life saving cancer interventions. The results could differ for 
cancer interventions that have large impacts on patients’ HRQoL.
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OBJECTIVES: The assessment of economic implications, both for individualized 
breast cancer (BC) prevention and for public health policy, of ﬁndings concerning the 
risk of BC cancer in women with CHEK2 heterozygosity. METHODS: Cost-
 effectiveness analysis of genotyping every women at CHEK2 and offering—on the 
basis of her BC risk proﬁle—a personalized screening programme in which the starting 
age would vary, versus present strategy, was perfomed using modelling technique. 
Two scenarios were compared: (A) DNA CHEK2 test in all women, screening strategy 
beginning at 25 years of age only in CHEK2-positive women (1.2%) and standard 
screening strategy (beginning at 50 years) in the remained population; (B) without 
DNA CHEK2 test, in all women standard screening strategy. Data on life expectancy, 
BC risk, efﬁcacy of screening strategy and medical costs were obtained from published 
literatures. The cohort simulation started with 25-year-old women and projected 
direct medical costs and outcomes over patients lifetimes. Effectiveness was measured 
as life years gained (LYG). Only direct medical costs (BC screening and treatment) 
were included, assessed from health care payer perspective and reported in PLN (1 
EUR  4.5 PLN in 2009). 5% and 3.5% discount rate was used for cost and effective-
ness, respectively. RESULTS: The total lifetime costs/patient were estimated to be 
2223.85 PLN (discounted: 644.84 PLN) in (A) and 1998.20 PLN (discounted: 
430.15 PLN) in (B). The total LYG generated with scenario (A) were 50.958 vs. 
50,939 with scenario (B) (without discounting) and 23,170 vs. 23,165 (discounted), 
respectively. This results in ICER for (A) of 11,862 PLN/LYG (without discounting) 
and 41,865 PLN/LYG (discounted). Results were robust to sensitivity analyses. CON-
CLUSIONS: The use of CHEK2genotyping and pesonalized BC screening improves 
survival compared to standard strategy and considering the suggested threshold for 
cost-effectiveness in Poland (80,000 PLN/LYG in 2008), is cost-effective in the Polish 
health care system.
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OBJECTIVES: Sorafenib is an oral multi-kinase inhibitor that targets tumour cell 
proliferation and tumour angiogenesis. In the TARGET study (phase III trial), 
sorafenib plus best supportive care (BSC) signiﬁcantly prolonged progression-free 
survival (PFS) compared with BSC alone in patients with unresectable and/or meta-
static renal cell carcinoma (mRCC). The objective of this study was to assess the 
cost-effectiveness of sorafenib plus BSC versus BSC alone in mRCC patients in Turkey. 
The study was undertaken from a Turkish health care payer perspective. METHODS: 
A Markov model was developed to estimate costs and outcomes associated with 
sorafenib  BSC and BSC alone. The model tracked patients with mRCC through 
three health states: PFS, disease progression and death. PFS and survival were extrapo-
lated based on patient level trial data (TARGET) over a patients’ lifetime. Health 
effects were expressed as life years gained (LYG). Incidence of adverse events (AEs) 
were also obtained from TARGET. Resource utilization data were obtained via expert 
clinical opinion and included physician visits, hospitalizations, monitoring, treatment 
of AEs, etc. Unit costs were taken from the Social Security Institution’s ofﬁcial price 
list. Costs and effects were evaluated over a lifetime and discounted at 3%. Results 
were presented as incremental cost/LYG. Deterministic and probabilistic sensitivity 
analyses were also conducted. RESULTS: The incremental survival beneﬁt with 
sorafenib was 1.269 LYG. The lifetime cost per patient was 4,080 TL for BSC and 
47,665 TL for sorafenib  BSC. The incremental cost-effectiveness ratio of sorafenib 
 BSC was 34,342 TL per LYG compared with BSC alone. Sensitivity analyses con-
ﬁrmed the robustness of the model results. CONCLUSIONS: Compared with BSC 
alone, sorafenib  BSC is a cost-effective therapy option in the treatment of unresect-
able and/or metastatic renal cell carcinoma (mRCC) patients in Turkey.
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OBJECTIVES: To compare costs and health beneﬁts of two therapeutic options for 
the ﬁrst line treatment of chemotherapy naïve patients with locally advanced or meta-
static non-small cell lung cancer (NSCLC)—gemcitabin/cisplatin versus pemetrexed/
cisplatin. METHODS: A lifetime 3-week cycle Markov model was developed and 
adapted for Portugal in order to estimate costs per life year (LY) and per quality 
adjusted life year (QALY) gained for patients with adenocarcinoma and large cell car-
cinoma histology. The model considers three disease states—stable, response, progres-
sion—and two treatment phases—during and after ﬁrst line treatment. Patients may 
suffer from adverse events such as neutropenia and febrile neutropenia; fatigue; diar-
rhoea; nausea and vomiting; bleeding; anaemia; and thrombocytopenia. The clinical 
inputs to the economic model were obtained from phase 3 pivotal trial. Direct medical 
costs were estimated according to both the Society’s and the NHS perspectives. 
A Delphi panel was conducted in order to estimate resource consumption. Unit costs 
were derived from ofﬁcial sources. RESULTS: Patients treated with pemetrexed 
have a discounted expected LY 1.226 compared to 1.104 of those treated with gem-
citabine. Due to the low quality of life of the population considered, QALY are 0.655 
and 0.595, respectively. Incremental costs with pemetrexed are below a3,900 for both 
perspectives due to its higher price and to a larger consumption of best supportive care. 
Therefore, the incremental cost per LY gained is a31,154 for the Society (a63,859 per 
QALY) and a30,950a for the NHS (a63,441a per QALY). Sensitivity analysis shows 
that these ﬁndings are only affected by the assumptions adopted on the mean body 
surface area, drug wastage and overall survival. CONCLUSIONS: The incremental 
cost per LY of pemetrexed is acceptable. However, the incremental cost per QALY is 
higher than usual thresholds due to the low basal quality of life of the population.
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OBJECTIVES: The aim of this study is to evaluate general practitioners’ prescription 
(GPs) of different Proton Pump Inhibitors (PPIs) in the period between 2005 to 2008. 
METHODS: Analysis has been performed on a database of 99 medical practitioners 
that have managed an average of 150.000 inhabitants. We evaluate the PPIs prescrip-
tions from January 2005 to December 2008. Evaluations performed are the following: 
1) PPI prescription (total and separately for lansoprazole, esomeprazole, pantoprazole, 
rabeprazole, and omeprazole); 2) prevalence of the reimbursement purpose (Gastro-
protection—G; Acid-Related Disease—ARD); 3) prevalence of patients with ARD 
categorized on the basis of PPI prescriptions as drugs box/year (1–3 short treat-
ment—ST; 4–11 long treatment—LT; 12 very long treatment—VLT). Data were 
expressed as Compound Annual Growth Rate (CAGR). RESULTS: The total volume 
of PPI’s prescribing increased progressively over the 4 years (CAGR 15%). The 
growth for each molecule was: L 42%; E 11%; P 16; R 3%; O 1%. The reim-
bursement purpose was signiﬁcantly higher for G (CAGR 41%) than for ARD 
(CAGR 6%; p  0.01). We found an increase of ARD patients with VLT with a sig-
niﬁcant highest CAGR (ST 3.9%, LT 4.8%, VLT 7.4%; p  0.01). PPI prescription 
showed a highest CAGR for L in all patients (27%), while the lowest one was for O 
in VLT patients (-9%). CONCLUSIONS: Generic PPIs has unexpectedly increased the 
prescription of whole drug class during the period 2005–2008. We observed a marked 
increase in a very long duration PPI treatment for ARD that caused a relevant resource 
consumption. Our data suggest that the appropriateness of PPI prescription after 
generic PPI introduction should be carefully monitored to distinguish between cost-
effective from cost-ineffective PPI treatment.
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OBJECTIVES: To estimate the impact of cost-containment reforms on R&D indica-
tors of pharmaceutical ﬁrms in eight countries and draw policy recommendations. 
METHODS: The average treatment effect on the treated is econometrically estimated 
with difference-in-difference (DiD); before-after comparisons; DiD with correlated 
random trend and a synthetic control group; kernel and nearest neighbour matching 
DiD methods. RESULTS: This study estimates short-term effects of recent regulatory 
changes in public health care on ﬁnancial indicators related to pharmaceutical R&D 
in Denmark, France, Germany, Italy, Japan, Norway, Sweden, and the US. The dataset 
represents a panel of ﬁnancial statements of 1306 pharmaceutical ﬁrms for the period 
1997–2007. The evaluated indicators include R&D expenditure, R&D expenditure 
to total revenue, cash ﬂow, gross margin, and price-to-book ratio. The national 
pharmaceutical expenditures, population, availability of credit for the private sector, 
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patent applications, and regulatory quality have been controlled for. Negative impacts 
of the recent reforms on R&D expenditures for Germany and Norway and, in some 
instances, for Italy and Japan are detected. A positive impact of the 2003 reform on 
R&D related indicators has been found for the US. The reforms reduced R&D expen-
ditures by 0.76% for Italian ﬁrms, decreased R&D intensity of Norwegian ﬁrms by 
2.42%, lowered cash ﬂows of French ﬁrms by 0.72%, but increased the R&D of 
American ﬁrms by 0.27%. These results can be explained by the degree of the reform 
rigidness for price and reimbursement controls, drug development lags, the importance 
of R&D for competition and ﬁrm valuation, and growing exports to less regulated 
markets. The results can also be explained with a theoretical R&D reproduction cycle 
model. CONCLUSIONS: Stronger shifts to more rigid cost-containment reimburse-
ments impeded R&D expenditures. However, despite the adverse regulatory shocks, 
most ﬁrms’ R&D related indicators tend to be persistent in the short run.
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OBJECTIVES: We investigated the impact of eliminating brand name drug coverage 
on statin drug spending, adherence, and physiologic outcomes in a cohort of Medicare 
beneﬁciaries, compared with a concurrent control group of beneﬁciaries with coverage 
of both brand and generic drugs. METHODS: All subjects were age 65 years. In 
2002–03, beneﬁciaries with restricted coverage had an annual drug beneﬁt cap of 
$1,000; in 2004–05, these beneﬁciaries lost brand name drug coverage, but had no 
coverage limits for generics. Controls had no restrictions or changes in brand/generic 
coverage 2002–05. We used ﬁxed-effects regression models to examine the association 
between coverage and quarterly outcomes. We adjusted for time-varying covariates 
including time, comorbidity (DxCG scores), plus time*coverage interactions. 
RESULTS: The 66,051 subjects had a mean age of 73.6 years, and 50% were female. 
In 2002, 53% of subjects had restricted beneﬁts, and the remaining had no drug beneﬁt 
restrictions. Compared to those with unrestricted beneﬁts and after multivariate adjust-
ment, subjects with restricted beneﬁts had less spending on and worse adherence to 
statin drugs, and worse LDL levels, particularly after the elimination of brand drug 
coverage: for example, statin drug spending differences were $35/quarter (95%CI: 
$32–37); the odds ratio of non-adherence was 1.27 (95% CI:1.19–1.36); and LDL 
differences were 2.00 mg/dL (95% CI:1.65–2.34 mg/dL) for subjects with restricted 
vs. unrestricted coverage, in Q4 2004 vs. Q1 2002. The LDL differences were related 
primarily to reductions in the prescribed daily dose among those with restricted cover-
age; in 2003, 10% of subjects had prescriptions above the maximum recommended 
dose of lovastatin, the only available generic during the study period. CONCLUSIONS: 
Prescription drugs within a therapeutic class are not all clinically equivalent, even 
within narrow classes with few differences such as statins. Careful attention is needed 
to the clinical needs of individual patients when imposing drug coverage restrictions.
PODIUM SESSION I: MENTAL HEALTH – MODELING STUDIES
MH1
A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE 
DISORDER—COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
Félix J1, Almeida J1, Varandas P2
1Exigo Consultores, Alhos Vedros, Lisbon, Portugal, 2Hospital dos Lusíadas, Lisbon, Portugal
OBJECTIVES: Most published cost-effectiveness analyses related to depression have 
used Markov models. However, evidence shows that probabilities of relapse and 
remission of depressive episodes are time and past events dependent, suggesting the 
appropriateness of discrete event simulation models (DESM). Our aim was to assess 
the cost-effectiveness of agomelatine in major depression from the Portuguese societal 
perspective using a DESM. METHODS: Sequential time to remission and time to 
relapse/recurrence were sampled from weibull distributions. Remission rates were 
obtained from a meta-analysis of randomized, venlafaxine-controlled clinical trials 
with either agomelatine, escitalopram, ﬂuoxetine, paroxetine or sertraline. Probability 
of relapse/recurrence was assumed dependent on the number of previous depressive 
episodes and time since last remission. We compared agomelatine 25 mg/day with 
possible dose titration to a mixed comparator composed by escitalopram(12 mg/- 
day), ﬂuoxetine(38 mg/day), paroxetine(25 mg/day), sertraline(116 mg/day) and 
venlafaxine(150 mg/day), weighted according to the deﬁned daily doses consumed 
between January and June 2008. Only direct costs were considered (drugs, medical 
visits, side effects treatments and monitoring). Effectiveness was measured in quality-
adjusted life years (QALY) and life years in remission (LYR). Time horizon varied 
from 6 to 37 months according to each individual simulation characteristics. When 
appropriate discount rates of 5%/year were applied to costs and effectiveness. 
RESULTS: A gain of 9.4 QALY (95%CI:[6.2;12.4]) or 10 LYR (95%CI:[5.2;15]) was 
estimated for each 100 patients treated with agomelatine. The estimated incremental 
cost of agomelatine treated patients was a325 (95%CI:[167; 827]). Corresponding 
incremental cost-effectiveness ratios were a3460/QALY or a3197/LYR. Probabilistic 
sensitivity analysis revealed 11% probability of agomelatine dominance and 97.5% 
of being cost-effective at a threshold of a10,000, regardless of the effectiveness measure 
considered. CONCLUSIONS: DESM is a valuable tool to model the cost-effectiveness 
of major depression. Agomelatine is a cost-effective drug for the treatment of major 
depressive disorder in Portugal, when compared to current clinical practice.
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OBJECTIVES: Depression causes a large burden of disease worldwide. Effective pre-
vention has the potential to reduce that burden considerably. We investigated the 
cost-effectiveness of minimal contact psychotherapy, based on Lewinson’s ‘Coping 
with depression’ course, targeted at opportunistically screened individuals with sub-
threshold (minor) depression. METHODS: We compared the costs and effects of an 
intervention scenario (all persons in the target population are screened and those with 
sub-threshold depression receive preventive minimal contact psychotherapy) with a 
current practice scenario. Using a Markov model, future health effects and costs were 
estimated from both the health care and the societal perspective. Incremental cost 
effectiveness ratios (ICER) were expressed in euro per DALY averted. Costs were dis-
counted at 4% and effects at 1.5%. The time horizon was ﬁve years. Probabilistic 
sensitivity analysis was employed to study the effect of uncertainty in the model 
parameters. RESULTS: From the health care perspective the incremental cost-
 effectiveness ratio was a4000 per DALY, and from the societal perspective the inter-
vention was even cost saving. CONCLUSIONS: This modeling study showed that 
from a health care perspective health gains can be achieved at a low cost if opportu-
nistic screening for sub-threshold depression in combination with MCP is implemented 
in a primary care setting. From a societal perspective, the modeled strategy of depres-
sion prevention is even cost saving.
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The association between the use of some antipsychotic drugs and diabetes mellitus is 
still controversial. OBJECTIVES: To assess the risk of diabetes mellitus in new users 
of antipsychotic drugs. METHODS: A nested case-control study using the Quebec 
Health Insurance Board databases. The source cohort was made of diabetes-free 
people who initiated antipsychotic treatment between January 1, 2000 and march 31, 
2007. Cases were cohort members who initiated antidiabetic treatment or had a 
diagnosis of diabetes during their follow-up period. Ten matched (for sex, age, year 
of treatment initiation) controls were selected using density sampling method. A 6-
value variable was used to assess exposure to antipsychotic: any typical, clozapine, 
olanzapine, quetiapine, risperidone or more than one drug. A paired multivariate 
logistic regression model was used to calculate adjusted odds ratios (OR). Co-variates 
included current user status, number of days of exposure to antipsychotic treatment, 
patient characteristics, use of other drugs and of health services. RESULTS: Among 
the 67,515 individuals included in the cohort, 1,715 cases of diabetes were identiﬁed 
and were matched to 17,143 controls. No difference was observed across atypical 
antipsychotic users. Longer exposure to any antipsychotic treatment was associated 
with diabetes [OR for each 30-day period: 1.05 (CI: 1.03–1.07)]. Individuals living in 
an urban area, those with low SES, those in the two highest tertiles of the number of 
different drugs used and of the number of medical visits, those who had been hospital-
ized, and those exposed q80% of the time period to drugs others than antipsychotic 
that can increase the risk of diabetes were more likely to develop the disease [OR: 
1.23 (CI: 1.03–1.46)]. CONCLUSIONS: Duration of exposure to antipsychotic treat-
ment is associated with diabetes, regardless of atypical antipsychotic agent. One limita-
tion to this analysis is that aripiprazole and ziprasidone were not available and thus 
no conclusion can be drawn.
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OBJECTIVES: To evaluate the impact of T2DM with comorbid depression on Patient 
Reported Outcomes (PROs) and health care resource use in France, Germany Italy, 
Spain and the UK. METHODS: Data were from respondents self-reporting diagnosis 
of T2DM in the 2008 U.S. National Health and Wellness Survey (NHWS), an annual 
cross-sectional survey of health care attitudes, behaviors, disease states, and outcomes 
of adults aged 18. Depression symptoms were deﬁned by afﬁrmative responses in the 
past month to: bothered by feeling down, depressed or hopeless and bothered by 
having little interest or pleasure in doing things. Outcomes included health care utiliza-
tion in the past six months and SF-12v2 summary scores. Regression models assessed 
independent effects of depression on outcomes and resource use, adjusting for gender, 
age, country, marital status, education, and an adjusted Charlson Comorbidity Index 
score. RESULTS: Among 2,668 respondents diagnosed with T2DM, 828 (31%) were 
female and 750 (28%) experienced symptoms of depression. After controlling for 
covariates, patients with comorbid depression had lower SF-12v2 physical and mental 
summary scores of 5.3 (p  0.0001) and 15.7 (p  0.0001), respectively; however, 
